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Abstract
Purpose Hyponatremia secondary to SIADH is frequent in
cancer patients and potentially deleterious. The aim of this
sub-analysis of the Hyponatremia Registry database is to an-
alyze current diagnostic and therapeutic management prac-
tices in cancer patients with SIADH.
Methods We analyzed 358 cancer patients who had serum
sodium concentration ([Na+]) ≤ 130 mEq/L and a clinical
diagnosis of SIADH from 225 sites in the USA and EU.
Results Precise diagnostic testing was performed in only 46%.
Almost 12% of all patients did not receive any hyponatremia
treatment. The most frequent therapies were fluid restriction
(20%), isotonic saline (14%), fluid restriction/isotonic saline
(7%), tolvaptan (8%), and salt tablets (7%). Hypertonic saline
was used in less than 3%. Tolvaptan produced the greatest
median rate of [Na+] change (IQR) (3.0 (4.7) mEq/L/day),
followed by hypertonic saline (2.0(7.0) mEq/L/day), and fluid
restriction/isotonic saline (1.9(3.2) mEq/L/day). Both fluid re-
striction and isotonic saline monotherapies were significantly
less effective (0.8(2.0) mEq/L/day and 1.3(3.0) mEq/L/day, re-
spectively) and were associated with clinically relevant rates of
treatment failure. Only 46% of patients were discharged with
[Na+] ≥ 130 mEq/L. Overly rapid correction of hyponatremia
occurred in 11.7%.
Conclusions Although essential for successful hyponatremia
management, appropriate diagnostic testing is not routinely per-
formed in current practice. The most frequently employed
monotherapies were often ineffective and sometimes even ag-
gravated hyponatremia. Tolvaptan was used less often but
showed significantly greater effectiveness. Despite clear evi-
dence that hyponatremia is associated with poor outcome in
oncology patients, most patients were discharged still
hyponatremic. Further studies are needed to assess the benefi-
cial impact of hyponatremia correction with effective therapies.
Keywords Hyponatremia . Syndrome of inappropriate
antidiuretic hormone secretion (SIADH) . Cancer . Fluid
restriction . Isotonic saline . Tolvaptan
Introduction
Hyponatremia is frequently observed in cancer patients and
can be explained by malignant disease itself, concomitant co-
morbidities, physical stress (e.g., pain), or medication [1–3].
In hospitalized cancer patients, hyponatremia is associated
with increased mortality and length of hospital stay, and
higher costs [4–10]. It is widely accepted that the syndrome
of inappropriate secretion of antidiuretic hormone (SIADH)
due to ectopic release of vasopressin accounts for the majority
of cases [11]. However, drugs including chemotherapies as
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well as targeted therapies [12], hypo- or hypervolemia, as well
as other less frequent disorders such as adrenal insufficiency,
myxedema, etc. must be ruled out as possible alternative
causes [13–15]. Diagnostic work-up is often viewed as com-
plex, and treatment is considered cumbersome and potentially
dangerous. However, despite the urgent need for better edu-
cation on how to approach the hyponatremic patient [16], no
evidence-based guideline for hyponatremia management spe-
cific to cancer patients is available. Current management strat-
egies are not well characterized.
The multinational Hyponatremia Registry (NCT01240668)
assessed the current state of treatment for euvolemic and
hypervolemic hyponatremia in real-world hospital settings.
This report focuses on the subgroup of patients with cancer
and SIADH with the aim to determine which diagnostic and
treatment modalities are employed, how effective they are, and




The study design has been described previously in detail [17,
18]. In brief, patients with euvolemic or hypervolemic
hyponatremia were enrolled from 146 US sites and 79 EU
sites. For the present publication, only patients initially
assessed as clinically euvolemic were analyzed. The study
was exclusively observational; no standardized diagnostic or
treatment protocols were imposed.
Inclusion and exclusion criteria
Only patients with clinically meaningful hyponatremia
([Na+] ≤ 130 mEq/L) and physician-diagnosed euvolemia
were enrolled. In a pre-specified adjudication process
[17], individuals whose medical file reports were incon-
sistent with the diagnosis of euvolemia were excluded.
Statistical methods
Mild hyponatremia was defined as 130mEq/ L≥ [Na+] > 125
mEq/L, moderate hyponatremia as 125 mEq/L ≥ [Na+] ≥ 120
mEq/L, and severe hyponatremia as [Na+] < 120 mEq/L.
Overly rapid correction of [Na+] was defined as an increase
>12 mEq/L in any 24-h interval or >18 mEq/L in any 48-h
interval. Rate of change of [Na+] was calculated as the total
increment in [Na+] during the treatment divided by the number
of treatment days.
Categorical variables were compared using a chi-square
test. In the case of more than two comparison groups, an
overall chi-square test was done before performing individual
pairwise chi-square tests
Nonparametric analysis was performed for continuous var-
iables. In case of more than two comparison groups, a
Kruskal-Wallis test was done to generate an overall test for
equality of medians followed by pairwise group comparisons.
For comparisons of only two groups, medians were compared
using the Wilcoxon Rank Sum Test. P values were not adjust-
ed for multiple comparisons.
Results
Of the 5028 patients enrolled between September 2010
and February 2013, 2847 patients had euvolemic
hyponatremia, and 586 of these (21%) were cancer-relat-
ed. After adjudication, 1597 were confirmed to have
euvolemic hyponatremia, SIADH being the most likely
cause in 1524 (95%). Two hundred twenty-eight cancer
patients initially labeled euvolemic were excluded during
adjudication. The 358 remaining patients diagnosed as
cancer-related SIADH constitute the primary analysis
group. The 1166 SIADH patients without a history of
cancer served as comparison group.
The most frequently reported types of cancer were lung
cancer (53.4%), tumors of the pituitary (5.5%), brain
(5.3%), head and neck (4.2%), and breast (3.4%)
(Supplemental Table 1). Patient demographics and clinical
characteristics are shown in Table 1. In contrast to the
non-cancer group, cancer-related SIADH patients were
more likely to be male and significantly younger.
Hyponatremia was present at hospital admission in more
than 80% and prior hyponatremia episodes had been re-
ported in more than 30%. Generalists or oncologists were
in charge of approximately 70% of all cases of cancer-
related SIADH and a hyponatremia expert, i.e., endocri-
nologist or nephrologist, was consulted in only 42.7%.
Although the median serum [Na+] at the time of diagnosis
was the same in both groups (124 mEq/L), significantly
more cases of severe hyponatremia were found in the
cancer group.
Appropriate diagnostic testing for SIADH requires the
assessment of the so-called Schwartz-Bartter criteria, i.e.,
serum and urinary osmolality and urinary sodium [15,
19]. In 13% of all cancer-related SIADH patients, none
of these tests was obtained; the complete trio was assessed
in only 46%. Diagnostic rigor was even worse in the sub-
groups comprising lung cancer patients and SCLC pa-
tients with all tests reported in 41 and 36%, respectively
(Supplemental Table 2).
While almost all cancer patients with severe hyponatremia
(99.1%) received active hyponatremia treatment, only 91 and
79% of patients with moderate or mild hyponatremia,
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respectively, were treated. The five most common active ther-
apies in the cancer-related SIADH group were fluid restriction
(FR, 20.1%), isotonic saline (NS, 13.5%), tolvaptan (7.9%),
salt tablets (ST, 6.5%), and FR + NS (6.5%). Sixty percent of
all treatment episodes and 74% of all initial episodes consisted
of a monotherapy. Hypertonic saline (HS) was used in only
2.2% overall and in 2.7% of cancer patients with severe
hyponatremia. Demeclocycline was prescribed in 2.3%,
0.3% (2) were prescribed conivaptan, and 0.5% (4) patients
received urea, 3 of which received it in combination with
another therapy. Stopping a medication that may induce
SIADH could also be considered an active treatment; of the
patients who received no other active hyponatremia therapy,
44% were receiving a potentially hyponatremia-inducing
medication (opiates 77%, antidepressants 16%, antiepileptics
2%), which was discontinued in 21%. Tolvaptan was chosen
relatively more often in lung cancer (7.9%) and in particular
SCLC patients (10.3%) than in the non-cancer group (6.2%)
while FR was used less often in cancer patients than in non-
cancer patients (Fig. 1).
With a median rate of [Na+] change (interquartile range,
IQR) of 3.0 (4.7) mEq/L/day and a median [Na+] increase of
Table 1 Baseline demographic and clinical characteristics for the primary analysis group, cancer subgroups, and non-cancer-related SIADH group
All cancer-related
SIADH (%) n = 358
Lung cancer patients
(%) n = 191
SCLC patients
(%) n = 90
Non-cancer-related
SIADH (%) n = 1166
Age distribution, n (%)a
≤50 years 35 (9.8) 11 (5.8) 3 (3.3) 151 (13.0)
51–64 years 125 (34.9) 76 (39.8) 46 (51.1) 248 (21.3)
65–74 years 106 (29.6) 61 (31.9) 27 (30.0) 233 (20.0)
≥75 years 92 (25.7) 43 (22.5) 14 (15.6) 534 (45.8)
Men, n (%)a 186 (52) 100 (52.4) 43 (47.8) 509 (43.7)
Prior hyponatremia, n (%)b
Yes 109 (30.4) 68 (35.6) 41 (45.6) 298 (25.6)
No 160 (44.7) 80 (41.9) 35 (38.9) 527 (45.2)
Unknown 89 (24.9) 43 (22.5) 14 (15.6) 341 (29.2)
Hyponatremia at admission, n (%)
Yes 288 (80.4) 166 (86.9) 82 (91.1) 964 (82.7)
No 65 (18.2) 24 (12.6) 7 (7.8) 188 (16.1)
Unknown 5 (1.4) 1 (0.5) 1 (1.1) 14 (1.2)
Primary physician specialty, n (%)a
Generalist 183 (51.1) 105 (55.0) 40 (44.4) 761 (65.3)
Oncologist 67 (18.7) 41 (21.5) 31 (34.4) 25 (2.1)
Endocrinologist 23 (6.4) 10 (5.2) 5 (5.6) 83 (7.1)
Nephrologist 15 (4.2) 7 (3.7) 2 (2.2) 67 (5.7)
Cardiologist 10 (2.8) 6 (3.1) 2 (2.2) 39 (3.3)
Other 60 (16.8) 22 (11.5) 10 (11.1) 190 (16.3)
Endocrinologist or nephrologist consulted, n (%)c
No 203 (56.7) 115 (60.2) 53 (58.9) 636 (54.5)
Yes 153 (42.7) 75 (39.3) 37 (41.1) 530 (45.5)
Median initial [Na+] (IQR), mEq/L 124 (10) 122 (10) 121 (10) 124 (8)
Median discharge [Na+] (IQR), mEq/La 130 (7.0) 130 (7.0) 131 (8.0) 132 (7.0)
[Na+] < 120 mEq/L, n (%) 108 (30.2) 71 (37.2) 41 (45.6) 299 (25.6)
Median initial creatinine (IQR), mg/dLa 0.67 (0.3) 0.62 (0.3) 0.61 (0.2) 0.73 (0.3)
Median initial urine [Na+] (IQR), mEq/L 76 (63.5) 76.5 (63.0) 72.0 (70.0) 71.5 (60)
Median initial urine osmolality (IQR), mOsm/kga 440 (266) 466 (252) 437 (279) 390 (255)
Median initial uric acid (IQR), mg/dL 2.8 (1.7) 2.8 (1.2) 2.3 (1.1) 2.8 (1.8)
BUN blood urea nitrogen, [Na+ ] sodium concentration, IQR interquartile range
a Cancer vs. non-cancer: P < 0.01
bHyponatremia during previous hospital admission in prior 12 months
c Hyponatremia specialist defined as nephrologist or endocrinologist
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4.0(8.0) mEq/L within the first 24 h after treatment initiation,
tolvaptan produced the most pronounced effect (P < 0.05 for
all comparisons except vs. HS; Table 2). Rates of change in the
two conivaptan patients were 3.7 and 11 mEq/L/day, similar to
tolvaptan. HS and FR + NS were equally effective (2.0 (7.0) and
1.9 (3.2) mEq/L/day, respectively). FR and NS alone were con-
siderably less effective (0.8 (2.0) and 1.3 (3.0) mEq/L/day, re-
spectively) while no treatment, salt tablets, and demeclocycline
were ineffective (0.1 (0.7), 0.1 (2.0), and 0.0 (2.3) mEq/L/d,
respectively). In patients with severe hyponatremia, HS showed
the greatest median rate of change (8.0 (6.4) mEq/L/day), follow-
ed by tolvaptan (3.3 (3.9) mEq/L/day), FR + NS (2.3 (3.0) mEq/
L/day), NS (2.0 (2.0) mEq/L/day), and FR (1.3 (2.5) mEq/L/
day). Regardless of the therapy chosen, the rate of [Na+] change
increased with lower baseline serum [Na+]. Tolvaptan elicited an
equivalent rate of change in both cancer and non-cancer groups.
In contrast, for all other therapies, the effectiveness was superior
in the non-cancer group.
Success and failure to control hyponatremia was assessed
categorically by analyzing the rate of reaching several clinically
relevant correction benchmarks (Table 3): aggravation (Δ
[Na+] > −2 mEq/L), ineffectiveness (Δ [Na+] within ±2 mEq/
L), and clinically relevant effectiveness (Δ [Na+] ≥ 5 mEq/L,
achievement of [Na+] > 130 mEq/L, normalization of [Na+]
(≥135 mEq/L). The pre-defined limits used as benchmark goals
were chosen based on clinical expertise. Tolvaptan was signifi-
cantly (P < 0.01 for most pairwise comparisons) more successful
than any other treatment with regard to these correction
benchmarks. A [Na+] > 130 mEq/L and normalization of [Na+]
were achieved in more than 73 and 39% of tolvaptan treatment
episodes, respectively. Moreover, a clinically meaningful in-
crease of [Na+] of ≥5 mEq/L was observed in almost 79%. For
any other treatment, success rates were about half as good at best
(41% for a [Na+] increase of ≥5 mEq/L with HS, <35% for all
other therapies). Conversely, tolvaptan showed a more than 50%
lower rate of correction failure (defined by the combined bench-
mark aggravation and ineffectiveness) compared to any other
therapy with less than 15%. The highest failure rate was reported
for no therapy (68%), followed by salt tablets (54%),
demeclocycline (52%), NS (47%), and FR (44%). With
tolvaptan, the results were almost identical in both the cancer
and the non-cancer group, while all other therapies seemed to
work better in non-cancer patients. Of note, the measurement of
the Schwartz-Bartter criteria had no impact on the correction
benchmark effectiveness (P = 0.50).
With better effectiveness came also higher rates of
overcorrection with tolvaptan (14%) and HS (16%); signifi-
cantly fewer cases of overcorrection occurred with the other
therapies. Overall (monotherapies and combination therapies
together), overly rapid correction was reported in 42 patients
(11.7%); in 29 of these cases, tolvaptan was employed and 11
patients received HS. No cases of osmotic demyelination syn-
drome were reported in the Hyponatremia Registry. No severe
adverse reactions were reported with the use of vaptans.
Given the better efficacy of tolvaptan and HS in individual



















































































Fig. 1 Most frequently chosen therapies in actively treated patients in the primary analysis group and subgroups
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determine if initial therapy containing one of these two highly
effective compounds, either as monotherapy or in conjunction
with slower acting therapies, was effective in increasing
[Na+]. With a tolvaptan-containing therapy, 59 and 53% of
patients with a starting [Na+] of ≤125 mEq/L or <120 mEq/
L, respectively, achieved a [Na+] > 130 mEq/L, while HS-
containing therapies, and the slow-acting treatments,
succeeded in only 18%/5% and 17%/14%, respectively
(P < 0.01, Fig. 2). The time needed to increase [Na+] to
>130 mEq/L in the patients who met this goal was 2 days
for tolvaptan- and HS-containing treatments, but 4 days for
other treatments (P < 0.01).
Irrespective of the therapy chosen, the median [Na+] at
discharge in the cancer group (130 (7.0) mEq/L) was signifi-
cantly (P < 0.001) lower than in the non-cancer group (132
(7.0) mEq/L). Only 46% of all cancer patients were
discharged with [Na+] above 130 mEq/L and only 23% with
a normalized [Na+] . In those discharged with a
[Na+] ≤ 130 mEq/L (i.e., the original threshold for inclusion
into the Registry), the median [Na+] was 127 (5) mEq/L; se-
vere hyponatremia was reported in 6% and moderate
hyponatremia in 32%. Median length of hospital stay was
longer (P < 0.001) in the cancer group (9 vs. 8 days), even
after adjusting for hyponatremia correction. With 8.7 vs.
1.9%, in-hospital mortality was significantly (P < 0.001) more
often reported in the cancer group than in the non-cancer-
group; the same was true for referral to hospice (1.9 vs.
0.8%; P < 0.001).
Discussion
The Hyponatremia Registry is the largest observational
hyponatremia study to date. The current analysis focuses on
the subgroup of cancer-related SIADH, which accounts for
approximately one third of all cases of SIADH. With 358
patients, this analysis represents the largest group of cancer
patients with SIADH ever studied.
Of note, 39% of all cancer patients initially enrolled as
euvolemic hyponatremia had to be excluded, mostly because
of clear signs of hypo- or hypervolemia. Thorough assessment
of volume status, however, is key for determining the cause of
hyponatremia [15, 20]. Although SIADH is a diagnosis of
exclusion, clinicians apparently readily interpret hypo-
natremia in cancer patients as SIADH without excluding al-
ternative causes. In addition, a minimal set of lab results [15,
Table 2 Response to most frequently utilized therapies, hypertonic saline and demeclocycline for all therapy episodes in cancer-related and non-
cancer-related SIADH (all patients and patients with severe hyponatremia)
[Na+] < 130 mEq/L [Na+] < 120 mEq/L



















No active treatment Cancer 41 129 (4.0) 0.1 (0.7) 8.0 (9.0) 1 1.3 9.0
Non-cancer 127 127 (6.0) 0.5 (1.0) 7.0 (7.0) 7 2.3 (3.1) 7.0 (9.0)
Fluid restriction Cancer 147 125 (9.0) 0.8 (2.0) 3.0 (4.0) 51 1.3 (2.5) 2.0 (4.0)
Non-cancer 601 125 (8.0) 1.0 (2.5) 2.0 (4.0) 176 1.7 (2.2) 3.0 (4.0)
Isotonic saline Cancer 110 123 (8.0) 1.3 (3.0) 1.5 (2.0) 29 2.0 (2.0) 1.0 (1.0)
Non-cancer 327 125 (8.0) 1.5 (3.7) 1.0 (1.0) 79 3.0 (5.0) 1.0 (1.0)
Tolvaptan Cancer 67 125 (8.0) 3.0 (4.7) 3.0 (4.0) 26 3.3 (3.9) 2.5 (3.0)
Non-cancer 158 127 (7.0) 3.0 (6.0) 2.0 (3.0) 32 2.2 (2.8) 3.0 (5.5)
Salt tablets Cancer 45 126 (10.0) 0.1 (2.0) 2.0 (3.0) 13 0.8 (2.0) 1.0 (1.0)
Non-cancer 71 128 (5.0) 0.8 (1.6) 3.0 (4.0) 11 1.1 (2.0) 2.0 (2.0)
Fluid restriction
+ isotonic saline
Cancer 50 121 (9.0) 1.9 (3.2) 1.0 (1.0) 20 2.3 (3.0) 1.0 (1.0)
Non-cancer 213 124 (8.0) 2.0 (4.0) 1.0 (1.0) 59 3.5 (5.3) 1.0 (1.0)
Hypertonic saline Cancer 18 121 (10.0) 2.0 (7.0) 1.0 (1.0) 8 8.0 (6.4) 1.0 (2.0)
Non-cancer 68 121 (9.5) 3.5 (5.8) 2.0 (2.0) 28 5.8 (5.9) 1.0 (1.0)
Demeclocycline Cancer 21 128 (8.0) 0.0 (2.3) 3.0 (2.0) 10 0.5 (3.0) 3.0 (2.0)
Non-cancer 31 124 (8.0) 0.3 (2.0) 4.0 (4.0) 13 0.6 (1.7) 3.0 (3.0)
P values <0.05:
Baseline sodium: No active treatment vs. FR, NS, tolvaptan, FR + NS, HS; FR vs. No active treatment, NS, FR + NS, HS; NS vs. No active treatment,
FR, salt tabs, demeclocycline; HS vs. No active treatment, FR, tolvaptan, salt tabs, demeclocycline; tolvaptan vs. No active treatment, FR + NS, HS; salt
tabs vs. NS, FR + NS, HS; FR + NS vs. No active treatment, FR, tolvaptan, salt tabs, demeclocycline; demeclocycline vs.. NS, HS, FR + NS
Median rate of change: No active treatment vs. FR, NS, tolvaptan, HS, FR + NS; FR vs. No active treatment, NS, tolvaptan, salt tabs, FR + NS, HS,
demeclocycline; NS vs. No active treatment, FR, tolvaptan, salt tabs, HS, demeclocycline; tolvaptan vs. No active treatment, FR, NS, salt tabs, FR + NS,
demeclocycline; salt tabs vs. FR, NS, tolvaptan, FR + NS, HS, demeclocycline; FR + NS vs. No active treatment, FR, tolvaptan salt tabs,
demeclocycline; HS vs. No active treatment, FR, NS, salt tabs, FR + NS, demeclocycline; demeclocycline vs. FR, NS, tolvaptan, salt tabs, FR + NS, HS
Duration of therapy: No active treatment vs. FR, NS, tolvaptan, salt tabs, FR + NS, HS, demeclocycline; FR vs. No active treatment, NS, FR + NS, HS;
NS vs. No active treatment, FR, tolvaptan, salt tabs, demeclocycline; tolvaptan vs. No active treatment, NS, FR+ NS, HS; Salt Tabs vs. No active
treatment, NS, tolvaptan, FR +NS; FR +NS vs. No active treatment, FR, tolvaptan, salt tabs, demeclocycline; HS vs. No active treatment, FR, tolvaptan,
demeclocycline; demeclocycline vs. No active treatment, NS, FR + NS, HS
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19, 21] is mandatory for a diagnosis of SIADH, but was
performed in only 46% and a hyponatremia expert was
consulted in only 43% of patients. In line with these find-
ings, sub-optimal management of hyponatremia in general
is widespread, as has been reported repeatedly [17, 22,
23]. However, in contrast to what we have previously
demonstrated in the overall SIADH population [24], prop-
er work-up of hyponatremia was not associated with
superior treatment effectiveness in the cancer-related
SIADH subgroup.
If the decision was made to treat hyponatremia (which
was not the case in 11.5%), the most frequently chosen
therapies were FR and NS, even in severe cases. Both
therapies led to only a modest [Na+] rise. However, al-
though considered ineffective and thus not recommended
for the treatment of SIADH, NS (1.3 (3.0) mEq/L/day) was
significantly more effective than FR (0.8 (2.0) mEq/L/
day), the recommended first-line SIADH therapy [15,
19]. Of note, the combination of both therapies worked
considerably better than either component alone with a
median [Na+] rise of 1.9 (3.2) mEq/L/day. Tolvaptan in-
creased [Na+] more rapidly (3.0 (4.7) mEq/L/day) than any
other therapy (P < 0.05). Two other popular treatment op-
tions, salt tablets and demeclocycline, were virtually non-
effective or even deleterious. Surprisingly, HS, the classic
treatment of severe hyponatremia, was administered in less
than 5% of initial treatments of such cases. However, in
that latter group, HS outperformed all other therapies (me-
dian [Na+] rise of 8.0 (6.4) mEq/L/day). Success rates for
reaching one of the three effectiveness benchmarks were at
least 1.9-fold higher with tolvaptan than with any other
therapy (P < 0.02). Consistently, the rate for reaching the
combined benchmark ineffectiveness or aggravation was
more than 50% lower with tolvaptan than with any other
treatment. Of note, the recommended first-line therapy, FR,
led to a relevant [Na+] decrease in 12%. Unacceptably high
rates of hyponatremia aggravation were also observed with
NS (8%), ST (14%), and demeclocycline (30%). In line
with current clinical practice, in which HS is used only as
initial treatment but replaced by other therapies once a
reasonable [Na+] increment has been achieved, the rate of
reaching a [Na+] of above 130 or even 135 mEq/L was low.
All employed therapies except tolvaptan appeared to be
less efficacious in the cancer group as compared to the non-
Table 3 Achievement of correction benchmarks by therapy episode and overcorrection in the cancer-related and the non-cancer-related SIADH group
Treatment Δ [Na+]
> −2 mEq/L (%)
Δ [Na+]







































































































































Within cancer-related SIADH group:
P values <0.01 for
Δ [Na+] > −2 mEq/L: tolvaptan vs. No treatment, and ST.
Δ [Na+]+/−2 mEq/L: tolvaptan vs. No treatment, FR, NS, FR + NS, and ST.
Δ [Na+] ≥ 5 mEq/L: tolvaptan vs. No treatment, FR, NS, ST, FR + NS, HS and demeclocycline
[Na+] > 130 mEq/L: tolvaptan vs. No treatment, FR, NS, ST, FR + NS, HS and demeclocycline; No treatment vs. NS
[Na+] > 135 mEq/L: tolvaptan vs. No treatment (p = 0.012), FR, NS, FR + NS, HS and demeclocycline. No treatment vs. NS; HS vs. demeclocycline
Overly rapid correction: No treatment vs. demeclocycline; tolvaptan vs. FR, NS; HS vs. NS
Cancer vs. non-cancer: P values <0.01 for Δ [Na+] > −2 mEq/L, Δ [Na+] ≥ 5 mEq/L, [Na+] > 130 mEq/L
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cancer group. Twomajor reasons may account for this. Firstly,
SIADH may be transient and a spontaneous improvement in
hyponatremia would be credited in our analysis to any
simultaneously administered hyponatremia treatment.
Hyponatremia secondary to cancer is less likely to be transient
in the short-term. Secondly, it is well known that the effective-
ness of the most frequently used therapy, FR, is reduced with
higher urine osmolality [14, 20, 25]; the median urine osmo-
lality was significantly higher (P < 0.001) in the cancer group
(440 mOsm/kg H2O) than in the non-cancer group (390
mOsm/kg H2O). Furthermore, NS is also known to be inef-
fective or counterproductive in SIADH and worsening of
hyponatremia is expected with higher urine osmolality [26].
In contrast, the predicted effect of a pharmacological approach
that blocks the vasopressin effect is largely independent of
baseline urine osmolality.
Consistent with what has been previously published,
our data indicate that treatment response is more pro-
nounced with lower baseline [Na+] values, irrespective
of the employed therapy [24]. This should be taken into
consideration when choosing a treatment in patients with
moderate/severe hyponatremia.
Since hyponatremia hampers anti-tumor therapy, af-
fects quality of life, interferes with treatment, and often
leads to unwanted hospital admissions or prolonged hos-
pital stays, rapid control of [Na+] is desirable. The rate of
reaching a safe [Na+] level in patients with clinically
relevant hyponatremia ([Na+] ≤ 125 mEq/L) was 3 times
as high if the initial therapy contained tolvaptan than
with treatments containing only slower-acting therapies
or HS-containing therapies. The time needed to reach a
[Na+] > 130 mEq/L was significantly shorter (2 days)
with a tolvaptan-containing therapy than with less effec-
tive therapies (4 days) (P < 0.01).
The price of high effectiveness is an increased rate of
overcorrection with the highly active therapies, tolvaptan
(14%) and HS (16%). Although there were no cases of osmot-
ic demyelination reported in the registry, this clearly indicates
that these therapies must be used with caution. In most cases
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had been employed concomitantly. Although it is contraindi-
cated to combine either tolvaptan or HS with other therapies,
results from the present study indicate that combination ther-
apies containing these compounds are chosen frequently by
clinicians.
Two vaptans, tolvaptan and conivaptan, have received ap-
proval for treatment of SIADH. In this Registry, only two
SIADH patients were treated with conivaptan. Due to differ-
ences in route of administration and dosing schedule, we did
not pool the data for these two compounds. However, it appears
likely that the effectiveness of both vaptans is similar. No safety
issues were reported with the use of vaptans in this registry.
The Hyponatremia Registry has a number of limitations,
most of which derive from its observational design [18].
Although patients were subject to adjudication by experts,
some uncertainty remains regarding the validity of the diag-
nosis Bcancer-related SIADH.^ Furthermore, potentially
hyponatremia-inducing drugs are highly prevalent and inter-
fere with diagnostic precision. However, since the study’s in-
tent was to capture Breal-world^ practice, this limitation does
not detract from observing how clinician-diagnosed SIADH
in the oncology setting is managed. As in other hyponatremia
trials, numerical changes of [Na+] were used as the primary
measure of effectiveness; neither symptoms nor clinical out-
come after therapy were reported routinely as it is extremely
difficult to assign these unambiguously to hyponatremia, es-
pecially in the oncology setting.
In summary, despite the high prevalence of hyponatremia
[1–3] and published guidance on its diagnosis and treatment
[11, 15, 19, 20], numerous shortcomings in current manage-
ment of hyponatremia in cancer-related SIADH are evident.
Hyponatremia in a cancer patient is readily assumed by clini-
cians to be due to SIADHwithout sufficient attention to accept-
ed diagnostic criteria. Moreover, many patients correctly diag-
nosed with SIADH do not receive any treatment for
hyponatremia at all, and a considerable number of patients are
discharged with unresolved hyponatremia. FR and NS are the
two most frequently used therapies but are ineffective in about
two thirds of cases. Of note, this lack of efficacy is more pro-
nounced in cancer patients than in non-cancer-related SIADH.
With the vaptans, a group of highly effective and yet safe com-
pounds is available and the findings of this analysis strongly
suggests that they should be viewed as first-line choice of treat-
ment. However, they are only used in the minority of cases in
current practice. We therefore conclude that there is a need to
focus educational efforts on (1) how to diagnose SIADH cor-
rectly, (2) the lack of uniform efficacy of FR andNS, (3) the use
of active treatments, and (4) increasing awareness of risk factors
for overcorrection. Despite clear evidence that hyponatremia is
associated with poor prognosis in particular in cancer patients,
proof of causation is still lacking. Future research efforts should,
therefore, focus on which cancer patients will benefit most from
correction of hyponatremia.
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